Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Runt-Related Transcription Factor 2 (Runx2) Is Responsible for Galectin-3 Overexpression in Human Thyroid Carcinoma.

Journal of cellular biochemistry | 2017

Runx2 promotes metastatic ability of cancer cells by directly activating some of the mediators regarding malignancy. Galectin-3 (Gal-3) extensively expressed in normal and transformed cells and it is responsible for many cellular processes. In this study, we aimed to investigate whether there is any relationship between runx2 transcription factor and regulation of galectin-3 expression in different human thyroid carcinoma cell lines. To show effects of runx2 transcription factor on gal-3 expression, we developed runx2 knockdown model in the thyroid carcinoma cell lines; anaplastic 8505C and 8305C and, papillary TPC-1 and follicular FTC-133 by using siRNA transfection. We analyzed the protein expressions and mRNA levels of gal-3 and MMP2/9 in the runx2-silenced cell lines using Western blotting, qPCR, and fluorescent microscopy. Our results showed that mRNA expression levels of gal-3 and MMP2/9 were downregulated in runx2-silenced cell lines. In this investigation, we revealed that regulation of gal-3 expression was strongly correlated with runx2 transcription factor in human thyroid carcinoma. Considering the contribution of human gal-3 in collaboration with MMP2/9 to the malignant characters of many cancers, regulation of their expressions through runx2 seems like one of the key regulatory mechanism for malignant potential of human thyroid carcinoma. Accordingly, runx2 transcription factor inhibitors can be a potential target in order to prevent gal-3 mediated malignancy of human thyroid carcinoma. J. Cell. Biochem. 118: 3911-3919, 2017. © 2017 Wiley Periodicals, Inc.

Pubmed ID: 28390192 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


goat anti-rabbit IgG-HRP (antibody)

RRID:AB_631746

This polyclonal targets goat anti-rabbit IgG-HRP

View all literature mentions

GAPDH Antibody (FL-335) (antibody)

RRID:AB_10167668

This polyclonal targets GAPDH

View all literature mentions

MMP-9 (H-129) (antibody)

RRID:AB_2266507

This polyclonal targets MMP9

View all literature mentions

MMP-2 (H-76) (antibody)

RRID:AB_2250826

This polyclonal targets MMP2

View all literature mentions

galectin-3 (H-160) (antibody)

RRID:AB_2136784

This polyclonal targets galectin-3 (H-160)

View all literature mentions

RUNX2 Antibody (C-12): sc-390715 (antibody)

RRID:AB_2637033

This monoclonal targets mouse, rat, human

View all literature mentions

8505C (cell line)

RRID:CVCL_1054

Cell line 8505C is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

FTC-133 (cell line)

RRID:CVCL_1219

Cell line FTC-133 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

8305C (cell line)

RRID:CVCL_1053

Cell line 8305C is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions